The U.S. Department of Health and Human Services (HHS) announced that Americans with high-risk exposures to Ebola will have access to an experimental antibody treatment known as MBP-134, developed by Mapp Biopharmaceuticals. This treatment has shown promise in animal studies but has yet to undergo human clinical trials. The current Ebola outbreak is concentrated in northeastern Democratic Republic of the Congo and Uganda. An American doctor infected with the virus is recovering in Germany, while another individual is quarantined in the Czech Republic. HHS is coordinating the shipment of MBP-134 under the FDA's investigational use mechanisms. The U.S. government is also setting up a quarantine facility in Kenya for potential Ebola cases, although this initiative has faced significant public backlash. Despite the urgency of the outbreak, the government has not yet confirmed whether MBP-134 will be used in clinical trials, although experts are hopeful it will be included in upcoming testing protocols. The situation continues to evolve as health officials work to manage the outbreak and ensure the safety of those at risk.